No Data
No Data
Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
RBC Capital Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $21
RBC Cuts Price Target on Apellis Pharmaceuticals to $21 From $24, Keeps Sector Perform Rating
Analysts Conflicted on These Healthcare Names: Apellis Pharmaceuticals (APLS), Skye Bioscience (SKYE) and Sarepta Therapeutics (SRPT)
Press Release: Apellis Announces Craig Wheeler to Join the Board of Directors
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $41